Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503226 | 1.00 | CD274 (0.32) | CD274NPC1RAB9A | |
| SCHEMBL9733790 | 0.84 | CD274 (0.33) | CD274NPC1RAB9A | |
| SCHEMBL26832986 | 0.81 | — | — | |
| SCHEMBL17024347 | 0.81 | — | — | |
| SCHEMBL11500645 | 0.80 | MEN1 (0.32) | CD274 | |
| SCHEMBL9735306 | 0.80 | MEN1 (0.32) | CD274 | |
| SCHEMBL9735303 | 0.80 | MEN1 (0.32) | CD274 | |
| SCHEMBL5553779 | 0.78 | DPP4 (0.35) | CD274NPC1RAB9A | |
| SCHEMBL28492715 | 0.78 | CD274 (0.35) | CD274NPC1RAB9A | |
| SCHEMBL28492716 | 0.78 | CD274 (0.35) | CD274NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024463-B1 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | NEUREN PHARMACEUTICALS LTD (NZ) | 2020-03-25 | — | — | EP | claimed |
| CN-116916921-A | Treatment of Prader-Willi syndrome | 诺仁制药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2022-12-08 | — | — | US | disclosed |
| CN-115243688-A | Bicyclic compounds and methods of their use in treating PITT HOPKINS syndrome | 诺仁制药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-4048264-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | Neuren Pharmaceuticals Limited (NZ) | 2022-08-31 | — | — | EP | disclosed |
| US-11197856-B2 | Bicyclic compounds and methods for their use in treating autism | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-12-14 | — | — | US | disclosed |
| WO-2021080646-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-04-29 | — | — | WO | disclosed |
| US-20200163961-A1 | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2020-05-28 | — | — | US | disclosed |
| EP-3024463-B1 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | NEUREN PHARMACEUTICALS LTD (NZ) | 2020-03-25 | — | — | EP | disclosed |
| US-10548892-B2 | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2020-02-04 | — | — | US | disclosed |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-05-24 | — | — | US | disclosed |
| US-9867823-B2 | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-01-16 | — | — | US | disclosed |
| US-20170020869-A1 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2017-01-26 | — | — | US | disclosed |
| EP-3024463-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | Neuren Pharmaceuticals Limited (NZ) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015013397-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-01-29 | — | — | WO | disclosed |
| US-8519127-B2 | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | NEUREN PHARMACEUTICALS LIMITED (AU) | 2013-08-27 | — | — | US | disclosed |
| WO-2011037644-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-03-31 | — | — | WO | disclosed |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | PMP22, IAPP, GCG | CD274 4326/4885NPC1 2943/4885RAB9A 2901/4885 |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | GRIN2C, GRIN2D, GRIN2A | CD274 4807/4885NPC1 2443/4885RAB9A 2777/4885 |
| US-10548892-B2 | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | GRIN2C, GRIN2D, GRIA2 | CD274 4811/4885NPC1 2899/4885RAB9A 2842/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | CD274 4812/4885NPC1 785/4885RAB9A 2743/4885 |
| US-11197856-B2 | Bicyclic compounds and methods for their use in treating autism | GRIN2C, ADCYAP1R1, GRIA2 | CD274 4704/4885NPC1 4321/4885RAB9A 3062/4885 |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | CD274 4812/4885NPC1 785/4885RAB9A 2743/4885 |
| US-20200163961-A1 | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | ADCYAP1R1, GRIN2C, ADCY2 | CD274 4733/4885NPC1 4333/4885RAB9A 3043/4885 |
| US-20170020869-A1 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | GRIN2C, GRIN2D, GRIN2A | CD274 4797/4885NPC1 2317/4885RAB9A 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.